Collegium Pharmaceutical, Inc. Q1 2026 Earnings Recap

COLL Q1 2026 May 9, 2026

Get alerts when COLL reports next quarter

Collegium Pharmaceutical’s stock rose 3.5% after the quarter, driven by stronger-than-expected growth in JORNAY prescriptions and accelerated revenue from the ADHD portfolio, supported by the imminent AZSTARYS acquisition.

Earnings Per Share Beat

$1.76 vs $1.52 est.

+15.8% surprise

Revenue Beat

193520000 vs 184470300 est.

+4.9% surprise

Market Reaction

1-Day -0.34%

See COLL alongside your other holdings

Add to your portfolio — free

Key Takeaways

JORNAY prescriptions grew 14% year-over-year, generating $38.9 million in net revenue, up 36% year-over-year.
Pain portfolio net revenues increased 4% year-over-year to $154.6 million, underpinning steady cash flow.
Total net product revenues rose 9%, with adjusted EBITDA also up 9% year-over-year.
Generated $57.1 million in cash from operations, ending the quarter with a strong cash position of $421.8 million, up $35 million sequentially.
Proposed acquisition of AZSTARYS is progressing, expected to close in Q2, and anticipated to enhance growth, margin expansion, and portfolio longevity through 2037.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit COLL on AllInvestView.